0000950170-23-070841.txt : 20231215 0000950170-23-070841.hdr.sgml : 20231215 20231215173820 ACCESSION NUMBER: 0000950170-23-070841 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231213 FILED AS OF DATE: 20231215 DATE AS OF CHANGE: 20231215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PATOU GARY CENTRAL INDEX KEY: 0001283535 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 231491552 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 4 1 ownership.xml 4 X0508 4 2023-12-13 0001582313 Xenon Pharmaceuticals Inc. XENE 0001283535 PATOU GARY 200 - 3650 GILMORE WAY BURNABY A1 V5G 4W8 BRITISH COLUMBIA, CANADA true false false false false Common Shares 2023-12-13 4 M false 6378 9.85 A 29951 D Common Shares 2023-12-13 4 F false 1278 39.68 D 28673 D Common Shares 2023-12-13 4 S false 5100 38.94 D 23573 D Common Shares 2023-12-13 4 M false 2880 9.85 A 26453 D Common Shares 2023-12-13 4 F false 577 39.68 D 25876 D Common Shares 2023-12-13 4 S false 2303 39.10 D 23573 D Common Shares 2023-12-13 4 M false 5144 9.00 A 28717 D Common Shares 2023-12-13 4 F false 1167 39.68 D 27550 D Common Shares 2023-12-13 4 S false 3977 39.84 D 23573 D Common Shares 2023-12-13 4 S false 7598 41.05 D 4902 I See Note Stock Option (Right to Buy) 9.85 2023-12-13 4 M false 6378 0 D 2016-12-31 2024-01-13 Common Shares 6378 0 D Stock Option (Right to Buy) 9.85 2023-12-13 4 M false 2800 0 D 2016-12-31 2024-01-13 Common Shares 2800 0 D Stock Option (Right to Buy) 9.00 2023-12-13 4 M false 5144 0 D 2017-11-04 2024-11-03 Common Shares 5144 0 D Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. /s/ Sherry Aulin, Attorney-in-fact 2023-12-15